The prescribed dosage of Elafibranor is one tablet a day, taken consistently at the same time. Credit: PeopleImages.com – Yuri A/Shutterstock. Ipsen has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for its Elafibranor (Iqirvo) for the […]
Ipsen’s Elafibranor gains MHRA approval for PBC treatment Read More »
Bayer will oversee the programme’s progression through further preclinical development and potential commercialisation. Credit: Lightspring/Shutterstock. Bayer has entered a strategic collaboration with MOMA Therapeutics to advance a small molecule oncology programme, leveraging the latter’s KNOMATIC platform. The partnership aims to
Bayer and MOMA Therapeutics partner for oncology programme Read More »
The long-acting injectable PrEP option is being rolled out at a record pace in sub-Saharan Africa and lower-income countries. Credit: elenavolf/Shutterstock. ViiV Healthcare has announced plans to triple its annual supply of long-acting cabotegravir for HIV pre-exposure prophylaxis (PrEP) to
ViiV Healthcare to increase annual supply of long-acting HIV PrEP Read More »
Limertinib is intended for the treatment of patients with lung cancer. Credit: New Africa/Shutterstock. Innovent Biologics and Jiangsu Aosaikang Pharmaceutical (ASK Pharm) have signed a strategic partnership agreement for the commercialisation of limertinib to treat lung cancer. Limertinib is an
Innovent and ASK Pharm partner to commercialise limertinib Read More »
The company is discontinuing all active trials of the sickle cell disease treatment, voxelotor, globally. Credit: Sebastian Kaulitzki/Shutterstock. Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease (SCD) from worldwide markets.
Pfizer to withdraw sickle cell treatment OXBRYTA from market Read More »
The newly approved indications of MSD’s pembrolizumab are non-small cell lung carcinoma (NSCLC) and radically unresectable urothelial carcinoma. Credit: Sonis Photography/Shutterstock. The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved MSD’s anti-programmed death receptor-1 (PD-1) therapy KEYTRUDA (pembrolizumab)
Japan approves MSD’s KEYTRUDA for lung and urothelial cancers Read More »
The collaboration is set to address translational questions and develop drug candidates for multiple cancer indications. Credit: metamorworks/Shutterstock. Finnish pharmaceutical company Orion has entered a partnership with Aitia to leverage artificial intelligence in drug discovery and simulation in the oncology
Orion and Aitia enter AI-driven oncology drug discovery partnership Read More »
The partnership aims to leverage both companies’ expertise in gene therapy technology. Credit: illustrissima/Shutterstock. Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has entered a strategic partnership with China-based Belief BioMed (BBM) to advance the development of new gene therapies. The
AskBio and Belief BioMed partner to advance gene therapies Read More »
Through this partnership, the companies intend to innovate new therapeutics and expedite the drug discovery and development process. Credit: Volha_R/Shutterstock. Generate:Biomedicines and Novartis have entered into a multi-target partnership, focusing on the discovery and development of protein therapeutics in multiple
Generate and Novartis partner for protein therapeutics development Read More »
The mpox vaccine is approved in in Canada, the European Union, Mexico, Singapore, Switzerland, the UK and the US. Credit: Creative Design nacional/Shutterstock. Bavarian Nordic has received a $63m contract from the US government to produce further bulk product and
Bavarian Nordic gains US contract for mpox vaccine manufacture Read More »
